Microsatellite instability - a useful diagnostic tool to select patients at high risk for hereditary non-polyposis colorectal cancer: a study in different groups of patients with colorectal cancer
C. Lamberti et al., Microsatellite instability - a useful diagnostic tool to select patients at high risk for hereditary non-polyposis colorectal cancer: a study in different groups of patients with colorectal cancer, GUT, 44(6), 1999, pp. 839-843
Background-Clinical diagnosis of hereditary non-polyposis colorectal cancer
(HNPCC) is based on a typical family history. As molecular genetic testing
is predominantly restricted to these families, gene carriers not meeting t
he clinical criteria may be missed.
Aims-To examine the value of microsatellite instability (MSI) as a tool to
increase the likelihood for uncovering a mismatch repair germline mutation
in patients with colorectal cancer and to identify a genotype-phenotype rel
ation in families with verified mutations.
Methods-Systematic search for germline mutations (hMSH2 and hMLH1 genes) wa
s performed in 96 patients: 57 fulfilled the Amsterdam criteria (group 1) a
nd 12 the looser HNPCC criteria (group 2). Seventeen patients showed famili
al clustering of cancers (group 3) and 10 patients under 50 years had spora
dic cancer (group 4), the latter of whom all exhibited MSI+ tumours.
Results-A similar proportion of germline mutations was found in patients wh
o fulfilled the clinical criteria of HNPCC and had MSI+ tumours (groups 1 a
nd 2; 15/39) compared with patients who did not meet these clinical criteri
a but who had MSI+ tumours (groups 3 and 4; 8/27 patients). Affected relati
ves of patients with hMLH1 mutations showed a significantly higher frequenc
y of colorectal cancer but a lower frequency of endometrium cancer than tho
se with hMSH2 mutations.
Conclusions-MSI in tumour tissue is a useful criterion for selecting patien
ts who should be tested for germline mutations in the mismatch repair genes
hMSH2 and hMLH1 irrespective of their family history. Among carriers of hM
SH2 mutations the tumour spectrum was broader than among carriers of hMLH1
mutations.